Bicycle Therapeutics reports 38% ORR for BT8009, 39% ORR for BT5528 in mUC; plans Phase 2/3 trial in Q1 2024

BICYCLE THERAPEUTICS PLC

BT8009 showed 38% ORR in 26 EV-naïve mUC patients; median duration of response 11.1 months; zero severe peripheral neuropathy.
BT7480 demonstrated two unconfirmed partial responses in cervical cancer and three prolonged stable disease (≥7 months).
BT5528 achieved 39% ORR in 18 mUC patients; median DOR 4 months; no bleeding events observed.
Plans to initiate Phase 2/3 Duravelo-2 registrational trial for BT8009 in mUC in Q1 2024.
Next-generation Bicycle conjugates in development; BRC imaging data expected in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.